Advancing combination therapies into clinical use.

Testing and treatment identification occur within WCG Precision Therapy through CytoVantage 3D. CTI Biopharma advances selected combinations into defined therapies and clinical development.

Role of CTI Biopharma

CTI Biopharma translates selected combinations into defined therapies, generates clinical evidence, and advances those therapies toward regulatory approval and use.

Clinical development

Design and execute clinical trials for selected three-drug therapies.

Evidence generation

Build the clinical data needed to validate response and support development.

Regulatory path

Advance therapies toward approval and commercial use.

CT30x Program
CT30x represents therapies developed from observed tumor response. CT301 is the first therapy in this series and is currently in clinical trials. Additional therapies will follow as new combinations are identified.

Important distinction

WCG Precision Therapy operates independently. Testing and treatment identification occur within WCG through CytoVantage 3D, where a broad range of therapies and combinations are evaluated.

Independent assay

CTI therapies are included in evaluation, but they are not predetermined outcomes.

Defined therapies

CTI Biopharma develops therapies where strong and repeatable activity is demonstrated.